TNFRSF11A and osteoporosis: This has resulted in clinical targeting of many of the molecules for autoimmune and inflammatory diseases (89), and approved drugs in blockers of TNF and LTα binding to TNFRI and TNFRII for RA, psoriasis, Crohn’s disease, and others; blockers of RANKL binding to RANK for osteoporosis; and blockers of BAFF binding to its receptors BAFFR, TACI, and BCMA for SLE.